Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,668 Million (Mid Cap)
22.00
NA
1.19%
-0.00
16.51%
3.80
Revenue and Profits:
Net Sales:
415 Million
(Quarterly Results - Sep 2025)
Net Profit:
119 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
36.28%
0%
36.28%
6 Months
29.44%
0%
29.44%
1 Year
25.33%
0%
25.33%
2 Years
10.31%
0%
10.31%
3 Years
27.41%
0%
27.41%
4 Years
94.57%
0%
94.57%
5 Years
0%
0%
0.0%
Aurisco Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.62%
EBIT Growth (5y)
27.33%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.51
Tax Ratio
12.85%
Dividend Payout Ratio
32.54%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.19%
ROE (avg)
13.03%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
3.61
EV to EBIT
19.43
EV to EBITDA
15.94
EV to Capital Employed
3.57
EV to Sales
5.65
PEG Ratio
4.83
Dividend Yield
1.31%
ROCE (Latest)
18.39%
ROE (Latest)
16.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
415.10
357.70
16.05%
Operating Profit (PBDIT) excl Other Income
140.70
136.20
3.30%
Interest
8.80
5.20
69.23%
Exceptional Items
1.90
0.70
171.43%
Consolidate Net Profit
118.60
95.20
24.58%
Operating Profit Margin (Excl OI)
339.00%
316.90%
2.21%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 16.05% vs -3.30% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 24.58% vs -29.95% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,471.20
1,258.20
16.93%
Operating Profit (PBDIT) excl Other Income
474.20
357.90
32.50%
Interest
16.80
3.60
366.67%
Exceptional Items
2.30
0.00
Consolidate Net Profit
354.80
289.10
22.73%
Operating Profit Margin (Excl OI)
261.00%
219.50%
4.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 16.93% vs 25.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 22.73% vs 38.79% in Dec 2023
About Aurisco Pharmaceutical Co., Ltd. 
Aurisco Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






